Loading stock data…
LEGN
$28.51+2.01 (+7.58%)
Pre-Market$28.71+0.20 (+0.70%)· Last close May 5
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Legend Biotech Corporation in the Healthcare sector is trading at $28.51. The stock is currently 37% below its 52-week high of $45.30, remaining 5.9% above its 200-day moving average. Technical signals show overbought RSI of 78 and bullish MACD crossover, explaining why LEGN maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 78) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$28.51
Potential Upside
5%
Whystock Fair Value$29.94
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Buy
Mean target$57.23+100.8%
Range$21.00 – $86.00
Fundamentals
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.80B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.08
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.62%
Volume
Today's trading volume
6.58M
Recent News
Is Legend Biotech (LEGN) Pricing Reflect Recent Share Rebound Or Longer Term Setbacks
If you are wondering whether Legend Biotech's current share price lines up with what the business might be worth, this article walks through the key valuation angles to help you frame that question clearly. Legend Biotech's stock last closed at US$28.51, with returns of 21.0% over the past week, 49.0% over the past month, 32.5% year to date, but a 9.1% decline over the past year and a 58.0% decline over three years. Recent headlines around Legend Biotech have focused on its position in the...
Is Legend Biotech’s Expanded Scientific Board Quietly Redefining Its Long-Term CAR-T Strategy (LEGN)?
Legend Biotech recently expanded its scientific advisory board, adding six high-profile experts in oncology, immunology, and cell therapy development to guide its next-generation pipeline and research priorities. This move underlines the company’s ambition to build an end-to-end cell therapy platform, potentially sharpening its focus on high unmet medical needs and innovation in CAR‑T and related technologies. We’ll now explore how this expanded scientific advisory board could influence...
Is Yum China a Buy After Investment Firm Matthews Purchased Shares Worth $12.57 Million?
Yum China operates thousands of quick-service and casual dining restaurants across China under well-known international brands.
Matthews Just Slashed Its Futu Position -- Here’s Why That Matters
Futu Holdings delivers digital brokerage and wealth management services to retail and institutional clients across Asia and global markets.
H.C. Wainwright Reaffirms Buy Rating for Legend Biotech (LEGN)
Legend Biotech Corp. (NASDAQ:LEGN) is one of the 10 best biotech stocks with highest upside potential. On April 20, H.C. Wainwright maintained its Buy rating for Legend Biotech Corp. (NASDAQ:LEGN). The firm has projected a target price of $50, which yields more than 109% potential upside for investors. It highlighted the company’s CAR-T therapies and […]